JP2013532658A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532658A5
JP2013532658A5 JP2013520785A JP2013520785A JP2013532658A5 JP 2013532658 A5 JP2013532658 A5 JP 2013532658A5 JP 2013520785 A JP2013520785 A JP 2013520785A JP 2013520785 A JP2013520785 A JP 2013520785A JP 2013532658 A5 JP2013532658 A5 JP 2013532658A5
Authority
JP
Japan
Prior art keywords
glyburide
administration
continuous infusion
medicament
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013520785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532658A (ja
JP6188021B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044397 external-priority patent/WO2012012347A2/en
Publication of JP2013532658A publication Critical patent/JP2013532658A/ja
Publication of JP2013532658A5 publication Critical patent/JP2013532658A5/ja
Application granted granted Critical
Publication of JP6188021B2 publication Critical patent/JP6188021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013520785A 2010-07-19 2011-07-18 グリブリドおよび他の薬剤の静脈内投与方法 Active JP6188021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
PCT/US2011/044397 WO2012012347A2 (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015212868A Division JP6179574B2 (ja) 2010-07-19 2015-10-29 グリブリドおよび他の薬剤の静脈内投与方法
JP2017051153A Division JP6506335B2 (ja) 2010-07-19 2017-03-16 グリブリドおよび他の薬剤の静脈内投与方法

Publications (3)

Publication Number Publication Date
JP2013532658A JP2013532658A (ja) 2013-08-19
JP2013532658A5 true JP2013532658A5 (enExample) 2015-05-28
JP6188021B2 JP6188021B2 (ja) 2017-08-30

Family

ID=45497399

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013520785A Active JP6188021B2 (ja) 2010-07-19 2011-07-18 グリブリドおよび他の薬剤の静脈内投与方法
JP2015212868A Active JP6179574B2 (ja) 2010-07-19 2015-10-29 グリブリドおよび他の薬剤の静脈内投与方法
JP2017051153A Active JP6506335B2 (ja) 2010-07-19 2017-03-16 グリブリドおよび他の薬剤の静脈内投与方法
JP2018230763A Active JP6795571B2 (ja) 2010-07-19 2018-12-10 グリブリドおよび他の薬剤の静脈内投与方法
JP2020019464A Pending JP2020073595A (ja) 2010-07-19 2020-02-07 グリブリドおよび他の薬剤の静脈内投与方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015212868A Active JP6179574B2 (ja) 2010-07-19 2015-10-29 グリブリドおよび他の薬剤の静脈内投与方法
JP2017051153A Active JP6506335B2 (ja) 2010-07-19 2017-03-16 グリブリドおよび他の薬剤の静脈内投与方法
JP2018230763A Active JP6795571B2 (ja) 2010-07-19 2018-12-10 グリブリドおよび他の薬剤の静脈内投与方法
JP2020019464A Pending JP2020073595A (ja) 2010-07-19 2020-02-07 グリブリドおよび他の薬剤の静脈内投与方法

Country Status (7)

Country Link
US (9) US8946293B2 (enExample)
EP (3) EP3339190A1 (enExample)
JP (5) JP6188021B2 (enExample)
KR (8) KR20230165363A (enExample)
CN (2) CN103108637B (enExample)
CA (3) CA2806069C (enExample)
WO (1) WO2012012347A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
CA2806069C (en) 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
HUE045889T2 (hu) 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) * 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
CN108348567B (zh) 2015-05-29 2022-03-01 马里兰州立大学巴尔的摩分校 减少或预防由内皮细胞的机械刺激所致的内膜损伤的方法
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Sur1-trpm4チャネル阻害剤による医療処置方法
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN120004770A (zh) 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DE10300323A1 (de) * 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
US8673964B2 (en) 2004-05-20 2014-03-18 Diamedica Inc. Use of drug combinations for treating insulin resistance
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド,ボルチモア NCCa−ATPチャネルを標的とする処置剤およびその使用方法
US10583094B2 (en) * 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
WO2006071781A2 (en) * 2004-12-23 2006-07-06 Hospira, Inc. Port closure system for intravenous fluid container
EP2071917B1 (en) 2006-09-29 2012-11-21 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CA2691199C (en) * 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
CN101229316B (zh) * 2008-01-31 2010-08-25 广东药学院 一种知母提取物
CA2806069C (en) 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Similar Documents

Publication Publication Date Title
JP6795571B2 (ja) グリブリドおよび他の薬剤の静脈内投与方法
ES2762250T5 (es) Tratamiento combinado del cáncer
Doepker et al. High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and beta-blocker overdose: a case series
JP2017031213A5 (enExample)
JP2014528474A5 (enExample)
JP2013541583A5 (enExample)
JP2019515908A5 (enExample)
JP2023120445A (ja) テルリプレシン組成物およびその使用方法
NZ598534A (en) Dosage regimen of an s1p receptor modulator
JP2012525393A5 (enExample)
JP2016539921A5 (enExample)
JP2018531938A5 (enExample)
JP2018513188A5 (enExample)
JP2016527202A5 (enExample)
RU2019134416A (ru) Фармацевтические композиции
JP2017533211A (ja) アマンタジン組成物を投与する方法
JP2014511365A5 (enExample)
JP2014510782A5 (enExample)
JPWO2021045159A5 (enExample)
JP2006514681A5 (enExample)
JP2014504601A5 (enExample)
RU2020140694A (ru) Способ лечения гипергликемии
JP2012517459A5 (enExample)
JP2013541582A5 (enExample)
JP2015507478A5 (enExample)